

# Anna Luisa Di Stefano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8016929/publications.pdf>

Version: 2024-02-01

56  
papers

2,532  
citations

201674

27  
h-index

197818

49  
g-index

58  
all docs

58  
docs citations

58  
times ranked

5177  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. <i>Nature Genetics</i> , 2017, 49, 789-794.	21.4	259
2	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 3307-3317.	7.0	230
3	Combined analysis of <i>TERT</i> , <i>EGFR</i> , and <i>IDH</i> status defines distinct prognostic glioblastoma classes. <i>Neurology</i> , 2014, 83, 1200-1206.	1.1	176
4	Chromosome 7p11.2 (EGFR) variation influences glioma risk. <i>Human Molecular Genetics</i> , 2011, 20, 2897-2904.	2.9	158
5	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. <i>British Journal of Cancer</i> , 2014, 111, 2024-2032.	6.4	158
6	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOV19). <i>European Journal of Cancer</i> , 2020, 141, 62-81.	2.8	122
7	Genome-wide association study identifies multiple susceptibility loci for glioma. <i>Nature Communications</i> , 2015, 6, 8559.	12.8	112
8	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014, 23, 6616-6633.	2.9	90
9	The evolution of headache from childhood to adulthood: a review of the literature. <i>Journal of Headache and Pain</i> , 2014, 15, 15.	6.0	85
10	The 2016 World Health Organization classification of tumours of the central nervous system. <i>Presse Medicale</i> , 2018, 47, e187-e200.	1.9	75
11	<i>IDH</i> -wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. <i>Neuro-Oncology</i> , 2021, 23, 955-966.	1.2	73
12	Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. <i>Neuro-Oncology</i> , 2018, 20, 907-916.	1.2	72
13	Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222. <i>British Journal of Cancer</i> , 2013, 108, 2178-2185.	6.4	51
14	Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. <i>Neuro-Oncology</i> , 2019, 21, 765-774.	1.2	51
15	Deciphering the 8q24.21 association for glioma. <i>Human Molecular Genetics</i> , 2013, 22, 2293-2302.	2.9	50
16	Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. <i>Neuro-Oncology</i> , 2013, 15, 542-547.	1.2	48
17	Diffuse gliomas with <i>FGFR3-TACC3</i> fusion have characteristic histopathological and molecular features. <i>Brain Pathology</i> , 2018, 28, 674-683.	4.1	48
18	<i>FGFR1</i> actionable mutations, molecular specificities, and outcome of adult midline gliomas. <i>Neurology</i> , 2018, 90, e2086-e2094.	1.1	47

#	ARTICLE	IF	CITATIONS
19	Gender-based blood transcriptomes and interactomes in multiple sclerosis: Involvement of SP1 dependent gene transcription. <i>Journal of Autoimmunity</i> , 2012, 38, J144-J155.	6.5	43
20	Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature. <i>Cancer Treatment Reviews</i> , 2014, 40, 951-959.	7.7	43
21	Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. <i>Acta Neuropathologica</i> , 2018, 135, 743-755.	7.7	42
22	Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. <i>Neuro-Oncology</i> , 2020, 22, 1614-1624.	1.2	41
23	Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. <i>Journal of Neuroimmunology</i> , 2011, 230, 160-163.	2.3	36
24	Predictive biomarkers in adult gliomas. <i>Current Opinion in Oncology</i> , 2013, 25, 689-694.	2.4	34
25	The clinical use of IDH1 and IDH2 mutations in gliomas. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 1041-1051.	3.1	34
26	TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. <i>Journal of Neuro-Oncology</i> , 2016, 126, 441-446.	2.9	30
27	VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 121, 499-504.	2.9	29
28	Stroke-like events after brain radiotherapy: a large series with long-term follow-up. <i>European Journal of Neurology</i> , 2019, 26, 639-650.	3.3	29
29	Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan. <i>PLoS ONE</i> , 2013, 8, e74345.	2.5	28
30	Acute late-onset encephalopathy after radiotherapy: An unusual life-threatening complication. <i>Neurology</i> , 2013, 81, 1014-1017.	1.1	25
31	Acute late-onset encephalopathy after radiotherapy: An unusual life-threatening complication. <i>Neurology</i> , 2014, 82, 1102-1102.	1.1	19
32	Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i> -mutant ganglioglioma. <i>Neurology</i> , 2018, 91, 523-525.	1.1	19
33	The French glioblastoma biobank (FGB): a national clinicobiological database. <i>Journal of Translational Medicine</i> , 2019, 17, 133.	4.4	19
34	Herpes simplex encephalitis in glioma patients: a challenging diagnosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 374-377.	1.9	17
35	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma. <i>Neurology</i> , 2019, 93, e1799-e1806.	1.1	17
36	Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan. <i>PLoS ONE</i> , 2014, 9, e90535.	2.5	17

#	ARTICLE	IF	CITATIONS
37	Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> <sup>V600E</sup> Mutant Adult Glial and Glioneuronal Tumors. <i>Neurology</i> , 2021, 97, e673-e683.	1.1	16
38	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. <i>Neuro-Oncology</i> , 2019, 21, 1039-1048.	1.2	13
39	Leveraging Ethnic Group Incidence Variation to Investigate Genetic Susceptibility to Glioma: A Novel Candidate SNP Approach. <i>Frontiers in Genetics</i> , 2012, 3, 203.	2.3	12
40	Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa141.	0.7	10
41	Meningeal Melanomatosis: A Challenge for Timely Diagnosis. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	9
42	An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	8
43	Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort. <i>Journal of Neuro-Oncology</i> , 2021, 153, 55-64.	2.9	8
44	Facing Contrast-Enhancing Gliomas: Perfusion MRI in Grade III and Grade IV Gliomas according to Tumor Area. <i>BioMed Research International</i> , 2014, 2014, 1-5.	1.9	6
45	Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas. <i>Current Opinion in Neurology</i> , 2018, 31, 727-732.	3.6	6
46	Gliomas. <i>BioMed Research International</i> , 2014, 2014, 1-2.	1.9	3
47	CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient. <i>Neuro-Oncology</i> , 2019, 21, 139-141.	1.2	3
48	Actionable targets involving FGF receptors in gliomas: Molecular specificities, spatial distribution, clinical outcome and radiological phenotype.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2005-2005.	1.6	3
49	Innovating Strategies and Tailored Approaches in Neuro-Oncology. <i>Cancers</i> , 2022, 14, 1124.	3.7	3
50	Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von) Tj ETQq0 0 0 rgBT /Oyerlock 10 Tf 50 222	1.9	2
51	EGFR gene amplification in monocentric and multicentric glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 145, 587-589.	2.9	1
52	Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials. <i>European Journal of Cancer</i> , 2022, 163, 98-107.	2.8	1
53	Non-invasive molecular diagnosis in gliomas with advanced imaging. <i>Clinical and Translational Imaging</i> , 0, , .	2.1	1
54	P07.15â€Diagnostic value of 2-hydroxyglutarate detection by 1H MR spectroscopy in patients with glioma and correlations with tumor phenotype and tissue dosage. <i>Neuro-Oncology</i> , 2016, 18, iv37-iv37.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Feasibility and benefit of molecularly-informed enrollment into early phase trials for patients with recurrent gliomas.. Journal of Clinical Oncology, 2018, 36, 2004-2004.	1.6	0
56	Automated Acquisition Planning for Magnetic Resonance Spectroscopy in Brain Cancer. Lecture Notes in Computer Science, 2020, 12267, 730-739.	1.3	0